Axicabtagene ciloleucel, up to 200 million autologous anti-cd19 car positive viable t cells, including leukapheresis and dose preparation procedures, per therapeutic dose
Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.
YESCARTA is an Oncology drug manufactured by Kite Pharma and administered via the Intravenous route of administration. The Q Code: Q2041 is aligned to the drug YESCARTA.
April 1, 2018
January 1, 2019